DNA methylation patterns delineate clinically relevant subgroups of meningioma. Paramasivam et al., previously established the six meningioma methylation classes (MC) benign 1-3, intermediate A and B, and malignant.
They set out to identify subgroup-specific mutational patterns and gene regulation. Whole-genome sequencing was performed on 62 samples across all MCs and WHO grades from 62 patients with matched blood control, including 40 sporadic meningiomas and 22 meningiomas arising after radiation (Mrad). RNA sequencing was added for 18 of these cases and chromatin-immunoprecipitation for histone H3 lysine 27 acetylation (H3K27ac) followed by sequencing (ChIP-seq) for 16 samples. Besides the known mutations in meningioma, structural variants were found as the mechanism of NF2 inactivation in a small subset (5%) of sporadic meningiomas, similar to previous reports for Mrad. Aberrations of DMD were found to be enriched in MCs with NF2 mutations, and DMD was among the most differentially upregulated genes in NF2 mutant compared to NF2 wild-type cases. The mutational signature AC3, which has been associated with defects in homologous recombination repair (HRR), was detected in both sporadic meningioma and Mrad, but widely distributed across the genome in sporadic cases and enriched near genomic breakpoints in Mrad. Compared to the other MCs, the number of single nucleotide variants matching the AC3 pattern was significantly higher in the malignant MC, which also exhibited higher genomic instability, determined by the numbers of both large segments affected by copy number alterations and breakpoints between large segments. ChIP-seq analysis for H3K27ac revealed a specific activation of genes regulated by the transcription factor FOXM1 in the malignant MC. This analysis also revealed a super enhancer near the HOXD gene cluster in this MC, which, together with general upregulation of HOX genes in the malignant MC, indicates a role of HOX genes in meningioma aggressiveness. This data elucidates the biological mechanisms rendering different epigenetic subgroups of meningiomas, and suggests leveraging homologous recombination repair (HRR) as a novel therapeutic target 1).
2: Ülgen E, Can Ö, Bilguvar K, Oktay Y, Akyerli CB, Danyeli AE, Yakıcıer MC, Sezerman OU, Pamir MN, Özduman K. Whole exome sequencing-based analysis to identify DNA damage repair deficiency as a major contributor to gliomagenesis in adult diffuse gliomas. J Neurosurg. 2019 Apr 5:1-12. doi: 10.3171/2019.1.JNS182938. [Epub ahead of print] PubMed PMID: 30952131.
3: Liang WS, Dardis C, Helland A, Sekar S, Adkins J, Cuyugan L, Enriquez D, Byron S, Little AS. Identification of therapeutic targets in chordoma through comprehensive genomic and transcriptomic analyses. Cold Spring Harb Mol Case Stud. 2018 Dec 17;4(6). pii: a003418. doi: 10.1101/mcs.a003418. Print 2018 Dec. PubMed PMID: 30322893; PubMed Central PMCID: PMC6318766.
4: Sizemore ST, Zhang M, Cho JH, Sizemore GM, Hurwitz B, Kaur B, Lehman NL, Ostrowski MC, Robe PA, Miao W, Wang Y, Chakravarti A, Xia F. Pyruvate kinase M2 regulates homologous recombination-mediated DNA double-strand break repair. Cell Res. 2018 Nov;28(11):1090-1102. doi: 10.1038/s41422-018-0086-7. Epub 2018 Oct 8. PubMed PMID: 30297868; PubMed Central PMCID: PMC6218445.
5: Yang B, Fu X, Hao J, Sun J, Li Z, Li H, Xu H. PAXX Participates in Base Excision Repair via Interacting with Pol β and Contributes to TMZ Resistance in Glioma Cells. J Mol Neurosci. 2018 Oct;66(2):214-221. doi: 10.1007/s12031-018-1157-4. Epub 2018 Sep 20. PubMed PMID: 30238427; PubMed Central PMCID: PMC6182633.
6: Motea EA, Fattah FJ, Xiao L, Girard L, Rommel A, Morales JC, Patidar P, Zhou Y, Porter A, Xie Y, Minna JD, Boothman DA. Kub5-Hera RPRD1B Deficiency Promotes “BRCAness” and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers. Clin Cancer Res. 2018 Dec 15;24(24):6459-6470. doi: 10.1158/1078-0432.CCR-17-1118. Epub 2018 Aug 14. PubMed PMID: 30108102; PubMed Central PMCID: PMC6295248.
7: Sharpe MA, Raghavan S, Baskin DS. PAM-OBG: A monoamine oxidase B specific prodrug that inhibits MGMT and generates DNA interstrand crosslinks, potentiating temozolomide and chemoradiation therapy in intracranial glioblastoma. Oncotarget. 2018 May 8;9(35):23923-23943. doi: 10.18632/oncotarget.25246. eCollection 2018 May 8. PubMed PMID: 29844863; PubMed Central PMCID: PMC5963626.
8: Pal S, Kozono D, Yang X, Fendler W, Fitts W, Ni J, Alberta JA, Zhao J, Liu KX, Bian J, Truffaux N, Weiss WA, Resnick AC, Bandopadhayay P, Ligon KL, DuBois SG, Mueller S, Chowdhury D, Haas-Kogan DA. Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. Cancer Res. 2018 Jul 15;78(14):4007-4021. doi: 10.1158/0008-5472.CAN-17-3691. Epub 2018 May 14. PubMed PMID: 29760046; PubMed Central PMCID: PMC6294442.
9: Waszak SM, Northcott PA, Buchhalter I, Robinson GW, Sutter C, Groebner S, Grund KB, Brugières L, Jones DTW, Pajtler KW, Morrissy AS, Kool M, Sturm D, Chavez L, Ernst A, Brabetz S, Hain M, Zichner T, Segura-Wang M, Weischenfeldt J, Rausch T, Mardin BR, Zhou X, Baciu C, Lawerenz C, Chan JA, Varlet P, Guerrini-Rousseau L, Fults DW, Grajkowska W, Hauser P, Jabado N, Ra YS, Zitterbart K, Shringarpure SS, De La Vega FM, Bustamante CD, Ng HK, Perry A, MacDonald TJ, Hernáiz Driever P, Bendel AE, Bowers DC, McCowage G, Chintagumpala MM, Cohn R, Hassall T, Fleischhack G, Eggen T, Wesenberg F, Feychting M, Lannering B, Schüz J, Johansen C, Andersen TV, Röösli M, Kuehni CE, Grotzer M, Kjaerheim K, Monoranu CM, Archer TC, Duke E, Pomeroy SL, Shelagh R, Frank S, Sumerauer D, Scheurlen W, Ryzhova MV, Milde T, Kratz CP, Samuel D, Zhang J, Solomon DA, Marra M, Eils R, Bartram CR, von Hoff K, Rutkowski S, Ramaswamy V, Gilbertson RJ, Korshunov A, Taylor MD, Lichter P, Malkin D, Gajjar A, Korbel JO, Pfister SM. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. 2018 Jun;19(6):785-798. doi: 10.1016/S1470-2045(18)30242-0. Epub 2018 May 9. PubMed PMID: 29753700; PubMed Central PMCID: PMC5984248.
10: Roos WP, Frohnapfel L, Quiros S, Ringel F, Kaina B. XRCC3 contributes to temozolomide resistance of glioblastoma cells by promoting DNA double-strand break repair. Cancer Lett. 2018 Jun 28;424:119-126. doi: 10.1016/j.canlet.2018.03.025. Epub 2018 Mar 22. PubMed PMID: 29574277.
11: Mukherjee J, Johannessen TC, Ohba S, Chow TT, Jones L, Pandita A, Pieper RO. Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma. Cancer Res. 2018 Jun 1;78(11):2966-2977. doi: 10.1158/0008-5472.CAN-17-2269. Epub 2018 Mar 15. PubMed PMID: 29545335.
12: Liang ML, Hsieh TH, Liu YR, Chen YW, Lee YY, Chang FC, Lin SC, Huang MC, Donald Ming-Tak H, Wong TT, Yen Y, Yang MH. Significance of cyclin D1 overexpression in progression and radio-resistance of pediatric ependymomas. Oncotarget. 2017 Dec 20;9(2):2527-2542. doi: 10.18632/oncotarget.23509. eCollection 2018 Jan 5. PubMed PMID: 29416789; PubMed Central PMCID: PMC5788657.
13: Romano FJ, Guadagno E, Solari D, Borrelli G, Pignatiello S, Cappabianca P, Del Basso De Caro M. ATM and p53 combined analysis predicts survival in glioblastoma multiforme patients: A clinicopathologic study. J Cell Biochem. 2018 Jun;119(6):4867-4877. doi: 10.1002/jcb.26699. Epub 2018 Feb 22. PubMed PMID: 29369420.
14: Conde M, Michen S, Wiedemuth R, Klink B, Schröck E, Schackert G, Temme A. Chromosomal instability induced by increased BIRC5/Survivin levels affects tumorigenicity of glioma cells. BMC Cancer. 2017 Dec 28;17(1):889. doi: 10.1186/s12885-017-3932-y. PubMed PMID: 29282022; PubMed Central PMCID: PMC5745881.
15: Chen G, Zhang B, Xu H, Sun Y, Shi Y, Luo Y, Jia H, Wang F. Suppression of Sirt1 sensitizes lung cancer cells to WEE1 inhibitor MK-1775-induced DNA damage and apoptosis. Oncogene. 2017 Dec 14;36(50):6863-6872. doi: 10.1038/onc.2017.297. Epub 2017 Sep 4. PubMed PMID: 28869605.
16: Ströbel T, Madlener S, Tuna S, Vose S, Lagerweij T, Wurdinger T, Vierlinger K, Wöhrer A, Price BD, Demple B, Saydam O, Saydam N. Ape1 guides DNA repair pathway choice that is associated with drug tolerance in glioblastoma. Sci Rep. 2017 Aug 29;7(1):9674. doi: 10.1038/s41598-017-10013-w. PubMed PMID: 28852018; PubMed Central PMCID: PMC5574897.
17: Zhang X, Huang Q, Wang X, Xu Y, Xu R, Han M, Huang B, Chen A, Qiu C, Sun T, Wang F, Li X, Wang J, Zhao P, Wang X. Bufalin enhances radiosensitivity of glioblastoma by suppressing mitochondrial function and DNA damage repair. Biomed Pharmacother. 2017 Oct;94:627-635. doi: 10.1016/j.biopha.2017.07.136. Epub 2017 Aug 5. PubMed PMID: 28787697.
18: Feng X, Matsuo K, Zhang T, Hu Y, Mays AC, Browne JD, Zhou X, Sullivan CA. MicroRNA Profiling and Target Genes Related to Metastasis of Salivary Adenoid Cystic Carcinoma. Anticancer Res. 2017 Jul;37(7):3473-3481. PubMed PMID: 28668836.
19: Sulkowski PL, Corso CD, Robinson ND, Scanlon SE, Purshouse KR, Bai H, Liu Y, Sundaram RK, Hegan DC, Fons NR, Breuer GA, Song Y, Mishra-Gorur K, De Feyter HM, de Graaf RA, Surovtseva YV, Kachman M, Halene S, Günel M, Glazer PM, Bindra RS. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci Transl Med. 2017 Feb 1;9(375). pii: eaal2463. doi: 10.1126/scitranslmed.aal2463. PubMed PMID: 28148839; PubMed Central PMCID: PMC5435119.
20: Zhai Y, Wei R, Liu J, Wang H, Cai W, Zhao M, Hu Y, Wang S, Yang T, Liu X, Yang J, Liu S. Drug-induced premature senescence model in human dental follicle stem cells. Oncotarget. 2017 Jan 31;8(5):7276-7293. doi: 10.18632/oncotarget.14085. PubMed PMID: 28030852; PubMed Central PMCID: PMC5352320.
21: Chen Y, Liu H, Zhang H, Sun C, Hu Z, Tian Q, Peng C, Jiang P, Hua H, Li X, Pei H. And-1 coordinates with CtIP for efficient homologous recombination and DNA damage checkpoint maintenance. Nucleic Acids Res. 2017 Mar 17;45(5):2516-2530. doi: 10.1093/nar/gkw1212. PubMed PMID: 27940552; PubMed Central PMCID: PMC5389581.
22: Berte N, Lokan S, Eich M, Kim E, Kaina B. Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence. Oncotarget. 2016 Oct 11;7(41):67235-67250. doi: 10.18632/oncotarget.11972. PubMed PMID: 27626497; PubMed Central PMCID: PMC5341871.
23: Koschmann C, Lowenstein PR, Castro MG. ATRX mutations and glioblastoma: Impaired DNA damage repair, alternative lengthening of telomeres, and genetic instability. Mol Cell Oncol. 2016 Apr 27;3(3):e1167158. doi: 10.1080/23723556.2016.1167158. eCollection 2016 May. PubMed PMID: 27314101; PubMed Central PMCID: PMC4909411.
24: Peng C, Chen Z, Wang S, Wang HW, Qiu W, Zhao L, Xu R, Luo H, Chen Y, Chen D, You Y, Liu N, Wang H. The Error-Prone DNA Polymerase κ Promotes Temozolomide Resistance in Glioblastoma through Rad17-Dependent Activation of ATR-Chk1 Signaling. Cancer Res. 2016 Apr 15;76(8):2340-53. doi: 10.1158/0008-5472.CAN-15-1884. Epub 2016 Mar 9. PubMed PMID: 26960975.
25: Zhang H, Liu Y, Zhou K, Zhou C, Zhou R, Cheng C, Wei Q, Lu D, Zhou L. Genetic variations in the homologous recombination repair pathway genes modify risk of glioma. J Neurooncol. 2016 Jan;126(1):11-17. doi: 10.1007/s11060-015-1892-0. Epub 2015 Oct 29. PubMed PMID: 26514363.
26: Crawley CD, Kang S, Bernal GM, Wahlstrom JS, Voce DJ, Cahill KE, Garofalo A, Raleigh DR, Weichselbaum RR, Yamini B. S-phase-dependent p50/NF-кB1 phosphorylation in response to ATR and replication stress acts to maintain genomic stability. Cell Cycle. 2015;14(4):566-76. doi: 10.4161/15384101.2014.991166. PubMed PMID: 25590437; PubMed Central PMCID: PMC4614791.
27: Kim JW, Kim JY, Kim JE, Kim SK, Chung HT, Park CK. HOXA10 is associated with temozolomide resistance through regulation of the homologous recombinant DNA repair pathway in glioblastoma cell lines. Genes Cancer. 2014 May;5(5-6):165-174. PubMed PMID: 25061500; PubMed Central PMCID: PMC4104759.
28: Feng Y, Zeng M, Xu Q. Association between XRCC3 T241M polymorphism and glioma risk: a meta-analysis. Tumour Biol. 2014 Jun;35(6):5589-92. doi: 10.1007/s13277-014-1738-y. Epub 2014 Mar 15. PubMed PMID: 24633885.
29: Guo P, Lan J, Ge J, Nie Q, Guo L, Qiu Y, Mao Q. MiR-26a enhances the radiosensitivity of glioblastoma multiforme cells through targeting of ataxia-telangiectasia mutated. Exp Cell Res. 2014 Jan 15;320(2):200-8. doi: 10.1016/j.yexcr.2013.10.020. Epub 2013 Nov 5. PubMed PMID: 24211747.
30: Liu J, Zhou Z, Lai T, Yin J. Association between XRCC3 Thr241Met polymorphism and risk of brain tumors: a meta-analysis. Tumour Biol. 2014 Feb;35(2):1083-7. doi: 10.1007/s13277-013-1144-x. Epub 2013 Sep 6. PubMed PMID: 24061639.
31: Wang XF, Liu S, Shao ZK. Effects of polymorphisms in nucleotide excision repair genes on glioma risk in a Chinese population. Gene. 2013 Oct 25;529(2):317-20. doi: 10.1016/j.gene.2013.07.025. Epub 2013 Jul 31. PubMed PMID: 23911298.
32: Yoshimoto K, Mizoguchi M, Hata N, Murata H, Hatae R, Amano T, Nakamizo A, Sasaki T. Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma. Front Oncol. 2012 Dec 5;2:186. doi: 10.3389/fonc.2012.00186. eCollection 2012. PubMed PMID: 23227453; PubMed Central PMCID: PMC3514620.
33: Zheng Z, Wang P, Wang H, Zhang X, Wang M, Cucinotta FA, Wang Y. Combining heavy ion radiation and artificial microRNAs to target the homologous recombination repair gene efficiently kills human tumor cells. Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):466-71. doi: 10.1016/j.ijrobp.2012.04.008. Epub 2012 Jun 1. PubMed PMID: 22658516.
34: Zheng Z, Ng WL, Zhang X, Olson JJ, Hao C, Curran WJ, Wang Y. RNAi-mediated targeting of noncoding and coding sequences in DNA repair gene messages efficiently radiosensitizes human tumor cells. Cancer Res. 2012 Mar 1;72(5):1221-8. doi: 10.1158/0008-5472.CAN-11-2785. Epub 2012 Jan 11. PubMed PMID: 22237628.
35: Zhou K, Liu Y, Zhang H, Liu H, Fan W, Zhong Y, Xu Z, Jin L, Wei Q, Huang F, Lu D, Zhou L. XRCC3 haplotypes and risk of gliomas in a Chinese population: a hospital-based case-control study. Int J Cancer. 2009 Jun 15;124(12):2948-53. doi: 10.1002/ijc.24307. PubMed PMID: 19330829.
36: Chen CC, Motegi A, Hasegawa Y, Myung K, Kolodner R, D'Andrea A. Genetic analysis of ionizing radiation-induced mutagenesis in Saccharomyces cerevisiae reveals TransLesion Synthesis (TLS) independent of PCNA K164 SUMOylation and ubiquitination. DNA Repair (Amst). 2006 Dec 9;5(12):1475-88. Epub 2006 Sep 20. PubMed PMID: 16990054.
37: Otomo T, Hishii M, Arai H, Sato K, Sasai K. Microarray analysis of temporal gene responses to ionizing radiation in two glioblastoma cell lines: up-regulation of DNA repair genes. J Radiat Res. 2004 Mar;45(1):53-60. PubMed PMID: 15133290.